

Melanoma Advisory Committee Interests Register

Publication Date: 6th July 2022

Name	Role with NICE	Type of interest	Description of interest	Interes t arose	Interest declared	Interest ceased	Comments
Andrew Molyneux	Guideline Chair	Nil	N/A	N/A	N/A	N/A	N/A
Guy Burkhill	Radiologist	Direct, Financial	Private reporting of oncological PET-CT scans for NHS facility. Scans are not specifically skin cases.	2017	March 2020	Ongoing	Declare and participate Rationale: Activity is generic and not specific to skin cancer Approved by SS
Guy Burkhill	Radiologist	Direct, Financial	Reporting PET-CT scans for Alliance Medical under NHS National contract. Scans are allocated randomly by Alliance Medical and include occasional Melanoma cases.	2015	March 2020	Ongoing	Declare and participate Rationale: Member has no control over the allocation of work which is largely not specific to skin cancer Approved by SS
Guy Burkhill	Radiologist	Indirect, Non- financial, professional and personal	Member of a Sarcoma Trial working group examining different intensity imaging regimes in Sarcoma Surveillance. I have been asked to advise on how to	Sept 2021	Sept 2021	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic




			define disease relapse on imaging. The trial is still in the planning phase. No payment is received for this work.				Approved by SS
Guy Burkhill	Radiologist	Direct, Financial	Provision of consultancy services for Rinnova (https://www.rinnova.co.uk/) I will be providing advice to Rinnova on research they are conducting into variations in practice in England in the utilization of PET-CT scanning. My advice will be remunerated.	9th Novem ber 2021	Novemb er 2021	Ongoing	Declare and participate Rationale: Guideline does not recommend PET-CT. Approved by CM
William Bolland	GP	Direct, Financial	Partner at Affinity Care – group practice – Shipley Yorkshire.	April 2018	Novemb er 2019	Ongoing	Declare and participate Rationale: Practice does not run clinics specific to skin cancer. Approved by SS
William Bolland	GP	Direct, Financial	Partners at Affinity Care have received funding from industry that is paid into the partnership – Funding has been variously provided for attendance at meetings by: Abbot, Bayer, Boehringer-Ingelheim, Bristol Myers	April 2018	Novemb er 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS




			Squibb, Dawn, INRStar, Medtronic, Oberoi Consulting, Pfizer, Roche, SanofiAventis, Servier Practice partner has a funding grant from Health Foundation Fund for Innovation which includes working in partnership Oberoi Consulting.Practice partner has a grant from Health Education England to support development of genetics education for primary care.				
William Bolland	GP	Direct, Financial	Work in a community dermatology clinic providing general dermatology and skin lesion services including minor surgery. The service is provided by Westcliffe health innovations with payment through Affinity Care.	Tbc	Novemb er 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS
William Bolland	GP	Indirect, Financial	A number of the partners at Affinity Care are board members and shareholders at Westcliffe Health Innovations.	Tbc	Novemb er 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS



William Bolland	GP	Indirect, Financial	Family member is a consultant in old age psychiatry, working for Leeds and York Partnership NHS Foundation Trust and conducts research (both within the NHS and in collaboration with pharmaceutical companies) in the field of dementia and mental health.	Tbc	Novemb er 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
William Bolland	GP	Indirect, Non- financial, professional and personal	 Colleagues at Affinity Care have the following interests: -GP Advisor to the Yorkshire and Humber -Dementia Strategic Clinical Network, -Clinical Lead Bradford Research Clusters 1&2 -GP on Y&H CRN Primary Care Steering Group -Clinical Lead Bradford& Airedale Research group (BARG) with BDCFT-undertaking commercial research 	April 2018	Novemb er 2019	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS



-Member of Older
People's Mental Health
Expert Advisory Group
-Honorary Visiting
Senior Research Fellow
Bradford University
School of Dementia
Studies
-Co-applicant
PROSPER research
trial.
-Member of the ASPIRE
Steering group
-Member of the LoTS-2-
CARE steering group
-Member of the AURAS-
AF steering group
prescribing
-Medical Advisor to AF
Association
-Medical Advisor to
STARS (The syncope
trust)
-Medical Advisor to
National Stroke
Association
-Medical Advisor to
Anticoagulation Europe




Twiston Life Dland the
-Trustee LifeBlood-the
thrombosis charity
-Executive of the
Arrhythmia Alliance
-Faculty member Heart
Valve Voice
-Living Longer Lives
Clinical Champion for
NHS-IQ
-Medical Advisor to
Yorkshire & Humber
AHSN for AF NIC
-Council Member of the
Yorkshire & Humber
Clinical Senate
-Standing member of
NICE Quality Standards
committee.
-Director, West Vertebire Medical
Yorkshire Medical
Services (WYMS) Ltd –
locum and resuscitation
training agency. In the
process of being wound
up.
-Director – Quality
Training Partnership.
Currently not trading.
WYMS Ltd has provided



			locum services and resuscitation training to GP Practices within the CCG. - GP clinical associate to NHSE sustainable improvement team. - LMC Representative for Bradford and Airedale District - CoR planning group Chair – Bradford Districts CCG. - Director/Vice Chair of YORLMC (North Yorkshire and Airedale and Bradford LMCs). - National lead for Primary Care genomics education at HEE.				
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Sanofi – Advisory Board. Working on non-melanoma MDT pathways and how to improve MDT process	2 nd Decem ber 2019	March 2020	2 nd Decemb er 2019	Declare and participate Rationale: Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder.




							Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Attended Pierre-Fabre funded educational conference – 9 th European post Chicago melanoma/skin cancer meeting	20 th June 2019	March 2020	21 st June 2019	Declare and participate Rationale: Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder. Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Speaker at Janssen funded educational event – prescribing workshop for non-medical prescribers	28 th June 2019	March 2020	28 th June 2019	Declare and participate Rationale: Interest not specific to scope of guideline update and has now ceased. No ongoing relationship with funder. Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Speaker at Bristol Myers- Squibb funded educational event – non-medical prescribing presentation: how to set up a new NHS clinic	5 th June 2019	March 2020	5 th June 2019	Declare and participate Rationale: Interest not specific to scope of guideline update and has now ceased. No ongoing relationship with funder.



							Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Speaker at Novartis funded educational event - non-medical prescribing presentation: how to set up a new NHS clinic	3 rd April 2019	March 2020	3 rd April 2019	Declare and participate Rationale: Interest not specific to scope of guideline update and has now ceased. No ongoing relationship with funder. Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Non-financial, professional and personal	British Oncology Pharmacy Association – treasurer on the executive committee. Non-paid position	13 th Octobe r 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Dharmisha Chauhan	Co-opted Pharmacist	Direct, Financial	Sanofi – Presentation on quality of life and toxicity management for cemiplimab for nonmelanoma skin cancer (cutaneous squamous cell carcinoma)	May 2021	28 th April 2021	28 th April 2021	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Susan Cheetham	Lay Member	Non-financial, professional and personal	Assist the charity SKCIN alongside the Macmillan Nurse in raising awareness in schools and colleges in	2017	March 2020	Ongoing	Declare and participate




			respect of skin care in the sun				Rationale: Not specific to any particular guideline topic Approved by SS
Fiona Collier	GP	Non-financial, professional and personal	GP Advisor to Hidradenitis Suppurativa Trust (charity) This is a nominal voluntary post, advising the charity on any medical matter relevant to hidradenitis suppurativa, a chronic skin disease.	2016	July 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Fiona Collier	GP	Non-financial, professional and personal	Principal Investigator for NHS Forth Valley for THESEUS, a NIHR-funded observational trial into current treatment of Hidradenitis Suppurativa, a chronic inflammatory skin condition. No direct relation to skin cancer, but is research on a dermatological topic.	2019	July 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Fiona Collier	GP	Indirect, Financial	Husband employed by Siemens UK (who manufacture CT and MRI machines) as a national technical support engineer. No shares owned.	N/A	Septemb er 2020	Ongoing	Declare and participate Rationale: Guideline will not make recommendations on purchasing of equipment



							and no shares in company are owned.
							Approved by SS
Gillian Godsell	Nurse	Nil	N/A	N/A	N/A	N/A	N/A
Sarah Hemington- Gorse	Plastic Surgeon	Nil	N/A	N/A	N/A	N/A	N/A
lan James	Lay Member	Non-financial, professional and personal	Member of Melanoma Patient Network Europe – A European patient network that educates and advocate for research and access in Melanoma across Europe	2015	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Ian James	Lay Member	Non-financial, professional and personal	Member and administrator of 'melanomamates' - patient support group hosted on Facebook	2013	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
lan James	Lay Member	Non-financial, professional and personal	Speaker at Melanoma Patient Conference UK – no payment	20 th June 2019	March 2020	20 th June 2019	Declare and participate Rationale: Not specific to any particular guideline topic



							Approved by SS
Lynne Jamieson	Histopathologist	Direct, Financial	Private Practice - histopathology reporting of cases for Spire Healthcare based at Spire Manchester Pathology. Reporting only on Dermatopathology (skin biopsy samples) and mirrors NHS practice. Constitutes approx. 5% of overall workload.	2007	March 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully Approved by SS
Lynne Jamieson	Histopathologist	Direct, Financial	Private Practice - histopathology reporting of outsourced cases from various healthcare organisations for Source Bioscience. Work mirrors NHS practice and constitutes 5 to 10% of overall workload.	2019	March 2020	Ongoing	Declare and participate Rationale: As above Approved by SS
Lynne Jamieson	Histopathologist	Direct, Financial	Private Practice – histopathology reporting of	2007	March 2020	Ongoing	Declare and participate



			cases sent via private clinics at Salford Royal Hospital. Work mirrors NHS practice and volume of work is very low.				Rationale: as above Approved by SS
Lynne Jamieson	Histopathologist	Non-financial professional and personal	Chair of the Specialty Advisory Committee for Dermatopathology for the Royal College of Pathologists advising the Royal College on matters arising in Dermatopathology. Subspecialty advisor providing stakeholder comment where necessary on National Guidelines drawn up by partner organisations which pertain to dermatopathology including NICE documents.	2016	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Lynne Jamieson	Histopathologist	Non-financial professional and personal	Chair of a sub- committee for Greater Manchester Cancer Skin pathway board on MDT reform. Document drafted on MDT reform in GM but not published yet	2018	March 2020	Ongoing	Declare and participate Rationale: Participation reviewed if MDT reform is discussed Approved by SS




Stephen Keohane	Dermatologist	Direct, Financial	Private Dermatology Practice which takes up 10% of overall work (90% work in NHS practice). Payment received per intervention and consultation. Practice mirrors NHS practice.	Novem ber 2019	Novemb er 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully Approved by SS
Stephen Keohane	Dermatologist	Direct, Financial	Roche Posay speaker meeting, not specific to guideline scope, honorarium received.	24 th March 2019	Novemb er 2020	24 th March 2019	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Stephen Keohane	Dermatologist	Non-financial professional and personal	President British Society of Dermatological Surgery	1 st July 2019	Novemb er 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic



							Approved by SS
Stephen Keohane	Dermatologist	Non-financial professional and personal	Chair Multi-professional guidelines committee for cutaneous Squamous Cell Carcinoma, administered by the British Association of Dermatologists.	1 st July 2016	Novemb er 2020	Ongoing	Declare and participate Rationale: Participation reviewed if cutaneous Squamous Cell Carcinoma reform is discussed Approved by SS
Stephen Keohane	Dermatologist	Non-financial professional and personal	Skin Cancer lead NHS E Specialised commissioning CRG for Dermatology	1 st August 2019	Novemb er 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Stephen Keohane	Dermatologist	Direct, Financial	Sanofi – Presentation on quality of life and toxicity management for cemiplimab for non- melanoma skin cancer (cutaneous squamous cell carcinoma)	May 2021	28 th April 2021	28 th April 2021	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
John Lear	Dermatologist	Direct, Financial	Private practice in general dermatology 1-2 sessions a week, NHS contract is 7 pa's per week.	2000	March 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the




							individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully Approved by SS
John Lear	Dermatologist	Direct, Financial	Mayne Pharma, LEO, Sanofi, Consultancy, Speaker fees for product in BCC/SCC and Gorlin syndrome, not melanoma	2018	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	CA209-192 phase III trial of nivolumab funded by BMS. Principle investigator for the study in Cambridge.	18 th Februar y 2015	March 2020	31 st Decemb er 2019	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	PI for Keynote 775 phase III for metastatic endometrial cancer using –	17 th Octobe r 2018	March 2020	Ongoing	Declare and participate



			pembrolizumab + lenvatinib funded by Merck.				Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	PI for ATHENA – phase III trial of maintenance treatment in ovarian cancer. Placebo controlled nivo/placebo v rucaparib/placebo, funded by CLOVIS.	27 th March 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Christine Parkinson	Medical Oncologist	Non-financial professional and personal	Local principle investigator for a melanoma trial 'CACTUS', an academic trial - no payment received. The trial randomizes BRAF mutant patient to investigator choice of first line treatment v dab+tram.	Novem ber 2021	Novemb er 2021	Ongoing	Declare and participate Rationale: non-paid academic involvement which does not impact guideline. Approved by CM
Howard Peach	Plastic Surgeon	Direct, Financial	Private practice through 'Peach Skin Clinic Ltd.' (sole Director) – Private practice constitutes 5% of workload (95% in NHS). Scope of private work reflects NHS practice. Charge is made per appointment /procedure.	2006	March 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a



							view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully Approved by SS
Howard Peach	Plastic Surgeon	Direct, Financial	Scientific advisory board – AMGEN	18 th Octobe r 2019	March 2020	18 th October 2019	Declare and participate Rationale: Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Trustee for charity 'Melanoma Focus'	2014	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Scientific committee member 'Melanoma Focus'	2014	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic




							Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	WYork &Harrogate Cancer Alliance representative	1 st May 2020	March 2020	01/05/2 020	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	PI - Minitub registration study, funded by the European Organisation for Research and Treatment of Cancer.	Aug 2012	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	PI - MelMarT melanoma excision margins trial - Pilot No funding in UK, overarching funding from Cancer Council New South Wales (CCNSW), Australia	July 2014	March 2020	Complet ed	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	PI - MelMarT melanoma excision margins trial – Main-Funding still being decided. Main Sponsor from CCNSW	TBC	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic




							Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Main author on current BAPRAS/BAD UK guidelines on melanoma	2010	March 2020		Declare and participate Rationale: Participation reviewed if BAD UK guidelines are discussed Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Advisor to NICE on Interventional Procedures for skin cancer	2012	March 2020	2015	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Chaired a multi-disciplinary meeting organised by Melanoma Focus – following which a UK Consensus statement on SNBx for cutaneous melanoma was published	Jan 2020	March 2020	Jan 2020	Declare and participate Rationale: Participation reviewed if SNBx for cutaneous melanoma is discussed Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Author on Ano-Uro-Genital Mucosal Melanoma guidelines published by Melanoma Focus	May 2018	March 2020	May 2018	Declare and participate Rationale: Participation reviewed if Ano-Uro-




							Genital Mucosal Melanoma guidelines are discussed Approved by SS
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Several papers, presentations and posters relating to melanoma management: A Mitra, S. E., J Smith, H Peach, M Marples & J Newton-Bishop (2010). "A case of epidermotropic metastatic melanoma simulating multiple primary melanomas." Peach AH et al (2019). "BAD Melanoma patient information leaflets." Alyss V Robinson1, C. K., Owen Thornton2, Howard Peach4, Maria Marples1,3, Donald J Dewar4,Ryckie G Wade1,4 (2017). "NLR and PLR as biomarkers for surveillance in cutaneous melanoma."Poster. Bevin Bhoyrul, G. B., Faye Elliott, Joanna McLorinan, Amy Wilson, Howard Peach, Bipin Mathew, Angana Mitra (2019). "Pathological review of primary cutaneous malignant melanoma by a specialist skin cancer multidisciplinary team improves	2007-2020	March 2020	Ongoing	Declare and participate Rationale: Participation will be reviewed in the event of any publications included in the evidence base. Approved by SS




patient care in the UK." J Clin Pathology: 5.
Fathology. 5.
Bramhall R.J., M. K. F., Peach
A.H.S. (2009). "Spontaneous
Regression of Metastatic
Melanoma." Poster.
Carbone A, W. R., Peach H
(2017). "A safe way to reduce the
length of hospital stay following
lymph node dissection for skin
malignancy: The Leeds
Experience." Presentation –
BAPRAS Finland.
F Al-Hassani, C. C., H.Peach
(2017). "Acral Lentiginous
melanoma - Is inflammation the
missing link?" JPRAS Open 14: 6.
Initissing link? JFTA3 Open 14. 0.
J.R. Marsden, J. A. NB., * L.
Burrows, M. Cook,à P.G. Corrie,§
N.H. Cox,- M.E. Gore,** P.
Lorigan, R. MacKie,àà P.
Nathan,§§ H. Peach,— B.
Powell*** and C. Walker (2010).
"Revised U.K.guidelines for the
management of cutaneous
melanoma 2010." British Journal
of Dermatology 163: 18.
Lo MCI, R. A., Wade RG, Peach
H, Dewar DJ, Heaton MJ,
Moncrieff MDS (2018). "The
Prognostic Significance of




Extracapsular Spread (ECS) in
Sentinel Node Positive (SLN+)
Patients forCutaneous
Melanoma." Society of Surgical
Oncology Annual
Symposium(Chicago, USA).
Macdonald, C. G., J.2; Brackley,
P.2 ; Cassell, O.3 ; Geh, J.4 ;
Odili, J.5; Peach, H.6;
Thompson, J.7; Wallace, D.8;
Moncrieff, M. (2013). "The Impact
on Quality of Life and
Reconstructive Need of Wider
Excision Margins >1 cm for
Primary Cutaneous Melanoma."
Journal der Deutschen
Dermatologischen Gesellschaft
11(Suppl 7.): 1.
· · · · · · ·
Mitra A, C. C., Walker C, Cook M,
Powell B, Lobo S, Chan M, Kissin
M, Layer G, Smallwood
J,Ottensmeier C, Stanley P,
Peach H, Chong H, Elliott F, Iles
MM, Nsengimana J, Barrett JH,
Bishop DT, Newton-Bishop JA.
(2010). "Melanoma sentinel node
biopsy and prediction models for
relapse and overall survival."
British Journal of Cancer Oct(130
(8)).
Moncrieff, M. D., et al. (2018). "1
Versus 2-cm Excision Margins for
pT2-pT4 Primary



CutaneousMelanoma (MelMarT): A Feasibility Study." Annals of Surgical Oncology 25(9): 2541- 2549.
Peach AH, M. M., Pritchard-Jones R (2020). "Advice for managing Melanoma patients during Coronavirus pandemic." BAPRAS March.
Peach, H. S., et al. (2013). "The unpredictability of lymphatic drainage from the ear in melanoma patients, and its implications for management." Ann Surg Oncol 20(5): 1707-1713.
RM Pinder, M. S., F Elliott, A Boon, C Topham, AHS Peach (2010). "Histopathological predictors of survival in node dissections in metastatic melanoma."
Robinson A, K. C., Peach H, Dewar D, Marples M, Wade R (2017). "Baseline neutrophillymphocyte,platelet- lymphocyte and lymphocyte- monocyte ratios did no predict survival in cutaneous malignant melanoma." Canadian Journal of Surgery 60(4).



Robinson AV, K. C., Peach H, Marples M, Dewar D, Wade RG (2017). "Baseline neutrophillymphocyte ratio is associated with metastases of
cutaneous melanoma to the sentinel lymphnode." Journal of the European Academy of
Dermatology and Venereology 31(46).
Robinson AV, K. C., Peach H, Marples M, Dewar D, Wade RG (2017). "Baseline
neutrophillymphocyte,platelet- lymphocyte and lymphocytemonocyte ratios
predict survival in cutaneous malignant melanoma." Journal of
the European Academy of Dermatology and Venereology 31(57).
Robinson, A. V., et al. (2020). "The neutrophil–lymphocyte ratio and locoregional melanoma:
amulticentre cohort study." Cancer Immunology, Immunotherapy.
Robinson AV, P. H., Wade RG (2018). "ASO Author Reflections: Haematological biomarkers in cutaneous melanoma." Annals of
Surgical Oncology 25(s3): 2.



S.M. Field, J. D., A Mitra, H.,
Peach, D. Dewar, J.A. Newton-
Bisho (2013). "A Clinical Audit of
theEffect of Targeted Advice and
Vitamin D Supplementation on
Serum Vitamin D Levels in
Patientswith Melanoma."
Smith, H., et al. (2020). "Ano-uro-
genital mucosal melanoma UK
national guidelines." European
Journal of Cancer 135: 22-30.
Smith, H., Bagwan I, Board R,
Peach H (2020). "Ano-uro-genital
mucosal melanoma UK national
guidelines." European Journal of
Cancer 135: 9.
Smith, H., et al. (2020). "Less Is
More – A Systematic Review of
the Outcomes of Radical Versus
Conservative Primary Resection
in Anorectal Melanoma."
European Journal of Surgical
Oncology 46(2): e13-e13.
Thomson CH, C. O., Peach H,
Holloway S, Garioch J, Moncrieff
M (2017). "Neuropathic pain and
quality of life after wide local
excision and sentinel lymph node
biopsy for melanoma: amulticentre
study." Melanoma Research 27: 5.
Stady. Moderna resourch 21.0.



			Wade, R. G., et al. (2018). "Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study." Annals of Surgical Oncology 25(11): 3341-3349. West CA., S. D., Peach H. (2014). "Combined clearance of Pelvic and superficial nodes for clinical groin melanoma." Journal of Plastic, Reconstructive and Aesthetic Surgery 67(12): 8.				
Howard Peach	Plastic Surgeon	Non-financial professional and personal	Advisory Board, MSD – discussing managing high risk stage II and all stage III/IV patients with systemic therapy	Oct 2021	Oct 2021	Jan 2022	Declare and participate Rationale: Interest not specific to scope of guideline update. No ongoing relationship with funder Approved by CM
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Advisory Board, Almirall, Psoriasis Biologic - honorarium payment	19th March 2019	March 2020	19th March 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and



							has ceased. No ongoing relationship with funder
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	CNS Meeting on psoriasis Janssen – speakers fee received.	16th June 2019	March 2020	16th June 2019	Approved by SS Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	British Dermatological Nursing Group 2019, Harrogate – sponsor Lilly funded- travel, accommodation and attendance costs.	25th June 2019	March 2020	27th June 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Workshop facilitation for psoriasis/ dermatology nurses, Novartis – payment received	23rd Novem ber 2019	March 2020	23rd Novemb er 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and



							has ceased. No ongoing relationship with funder
							Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Webinar / psoriasis— Janssen- payment received	16th Septem ber, 21st & 27th of Novem ber, 3rd Decem ber 2019	March 2020	3rd Decemb er 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Janssen-Cilag Limited, EADV 2019- travel, accommodation and attendance costs	9 th Octobe r 2019	March 2020	13th October 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Meeting Novartis- psoriasis – payment received.	30 th Januar y 2020	March 2020	30 th January 2020	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and



							has ceased. No ongoing relationship with funder
							Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Teaching on MSc Dermoscopy module , University Hertfordshire – unpaid Once to twice yearly	May 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Physical Examination Day for Skin Cancer CNS's, University of Hertfordshire - unpaid	4 th July 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Organising Annual Conference British Association Skin Cancer Nurse Specialists	Novem ber 2019	March 2020	Ongoing	Declare and participate Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Non-financial professional and personal	Organising national skin cancer study days for British Dermatological Nursing Group	Novem ber 2019	March 2020	Ongoing	Declare and participate




							Rationale: Not specific to any particular guideline topic Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Attended the BAD Virtual Conference by Eli Lilly – registration fee received.	Septem ber 2020	Septemb er 2020	N/A	Declare and participate Rationale: Interest not specific to scope of guideline update. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Attended British Association of Dermatologists (BAD) conference – registration fee covered by UCB Pharma.	July 2021	Aug 2021	July 2021	Declare and participate Rationale: Interest not specific to scope of guideline update. No ongoing relationship with funder Approved by SS
Saskia Reeken	Clinical Nurse Specialist	Direct, Financial	Attended British Dermatological Nursing Group conference – registration fee covered by AbbVie.	Sept 2021	Aug 2021	Sept 2021	Declare and participate Rationale: Interest not specific to scope of guideline update. No




							ongoing relationship with funder Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Advisory Board, Amgen (T-VEC therapy). One off payment received.	18 th Octobe r 2019	March 2020	18 th October 2019	Declare and participate Rationale: Interest not specific to scope of guideline update, occurred prior to appointment and has ceased. No ongoing relationship with funder Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Partner, HCA Joint Venture, Chiswick Medical Centre LLP(https://www.hcahealthcare.co.uk/facilities/the-harley-street-clinic/centres-and-teams/chiswick-medical-centre) 0.4% Shareholding. Chiswick is a diagnostic centre, providing standard medical care. Clinic is a general clinic that reflects NHS scope of practice.	27 th Novem ber 2017	March 2020	Ongoing	Declare and participate Rationale: Private practice in this area is a small proportion of the individual's overall practice and mirrors their NHS work. Based on the need for the committee member's expertise and a view that the potential for gain is minimal, in this instance NICE has confirmed that the individual can continue to participate fully.




							Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Private practice which mirrors NHS scope of practice, 10%.90% of work NHS - 11Pa's NHS.	Februar y 2017	March 2020	Ongoing	Declare and participate Rationale: As above
							Approved by SS
Myles Smith	General Surgeon	Non-financial professional and	RCS Surgical Tutor at RMH.	Octobe r 2016	March 2020	Ongoing	Declare and participate
		personal					Rationale: Not specific to any particular guideline topic
							Approved by SS
Myles Smith	General Surgeon	Non-financial professional and personal	1: Smith HG, Glen J, Turnbull N, Peach H, Board R, Payne M, Gore M, Nugent K, Smith MJF. Less is more: A systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma. Eur J Cancer. 2020 Aug;135:113-120. doi: 10.1016/j.ejca.2020.04.041. Epub 2020 Jun 18. PMID: 32563895.	2007-2020	Septemb er 2020	N/A	Declare and participate Rationale: Participation will be reviewed in the event of any publications included in the evidence base. Approved by SS
			2: Snow H, Hazell S, Francis N, Mohammed K,				




O'Neill S, Davies E, Mansfield D, Messiou C, Hujairi N, Nicol D, Harrington K, Smith M. Prostate-specific membrane antigen expression in melanoma metastases. J Cutan Pathol. 2020 Jun 11. doi: 10.1111/cup.13774. Epub ahead of print. PMID: 32529651.
3: Smith HG, Bagwan I, Board RE, Capper S, Coupland SE, Glen J, Lalondrelle S, Mayberry A, Muneer A, Nugent K, Pathiraja P, Payne M, Peach H, Smith J, Westwell S, Wilson E, Rodwell S, Gore M, Turnbull N, Smith MJF. Ano-uro-genital mucosal melanoma UK national guidelines. Eur J Cancer. 2020 Aug;135:22- 30. doi: 10.1016/j.ejca.2020.04.030. Epub 2020 Jun 9. PMID: 32531566.
4: Smith MJF, Smith HG, Joshi K, Gore M, Strauss DC, Hayes AJ, Larkin J. The impact of effective



systemic therapies on surgery for stage IV melanoma. Eur J Cancer. 2018 Nov;103:24-31. doi: 10.1016/j.ejca.2018.08.008. Epub 2018 Sep 7. PMID: 30196107.
5: Snow HA, Hofman MS, Mitchell CA, Gyorki DE, Smith MJF. Incidental Metastatic Melanoma Identified on 68Ga- Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer. Clin Nucl Med. 2018 Jul;43(7):509-511. doi: 10.1097/RLU.0000000000 02111. PMID: 29742609.
6: Smith HG, Wilkinson MJ, Smith MJF, Strauss DC, Hayes AJ. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies. Eur J Cancer. 2018 Sep;100:46-54. doi: 10.1016/j.ejca.2018.04.014. Epub 2018 Jun 22. PMID: 29940423.



7: Arce Vargas F, Furness
AJS, Litchfield K, Joshi K,
Rosenthal R, Ghorani E,
Solomon I, Lesko MH, Ruef
N, Roddie C, Henry JY,
Spain L, Ben Aissa A,
Georgiou A, Wong YNS,
Smith M, Strauss D, Hayes
A, Nicol D, O'Brien T,
Mårtensson L, Ljungars A,
Teige I, Frendéus B;
TRACERx Melanoma;
TRACERx Renal;
TRACERx Lung consortia,
Pule M, Marafioti T, Gore
M, Larkin J, Turajlic S,
Swanton C, Peggs KS,
Quezada SA. Fc Effector
Function Contributes to the
Activity of Human Anti-
CTLA-4 Antibodies. Cancer
Cell. 2018 Apr 9;33(4):649-
663.e4. doi:
10.1016/j.ccell.2018.02.010.
Epub 2018 Mar 22. PMID:
29576375; PMCID:
PMC5904288.
8: Arce Vargas F, Furness
AJS, Solomon I, Joshi K,
Mekkaoui L, Lesko MH,
Miranda Rota E, Dahan R,
Georgiou A, Sledzinska A,
Ben Aissa A, Franz D,




Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA. Fc-Optimized Anti-CD25 Depletes Tumor- Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.0 13. Epub 2017 Apr 11. PMID: 28410988; PMCID: PMC5437702.
9: Moran DE, Smith MJ, O'Sullivan MJ, Bannon H, Crotty TB, Collins CD, Skehan SJ, O'Higgins N, McDermott EW, Evoy D, Hill AD. Sentinel lymph node biopsy in elderly irish patients with malignant



			melanoma. Ir Med J. 2007 Apr;100(4):422-4. PMID: 17566474.				
Myles Smith	General Surgeon	Indirect, Financial	Updated the melanoma text on melanoma online, and recently ECT for Cancer research UK. Reimbursement fund was directed to the Sarcoma and Melanoma Research Fund.	2020	Septemb er 2020	N/A	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS
Myles Smith	General Surgeon	Non-financial professional and personal	Updated Macmillan online text with regards to Anorectal melanoma.	2020	Septemb er 2020	N/A	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS
Myles Smith	General Surgeon	Direct, Financial	BRC Research Fellow Grant for Preoperative Planning PSMA-PET in Melanoma Surgery (PPPIMS). Fellowship planned to start in October 2021.	9 th April 2021	Sept 2021	Will cease 31st March 2022	Declare and participate Rationale: Not specific to any particular guideline topic. Approved by SS
Myles Smith	General Surgeon	Direct, Financial	BRC pump priming grant to be received for the project: Preoperative Planning PSMA-PET in Melanoma	March 2021	Sept 2021	Will cease 31 st March 2022	Declare and participate Rationale: Not specific to any particular guideline topic.



			Surgery (PPPIMS). Project reference: B130. Funds not yet transferred yet as the project and fellowship have not started.				Approved by SS
Myles Smith	General Surgeon	Direct, Financial	Attendance at iSPIES conference in Amsterdam, a Stryker event, related to fluorescence guided surgery (FSG). Travel, attendance and accommodation paid for by Stryker.	18 th Octobe r 2021	Novemb er 2021	19 th October 2021	Declare and participate Rational: Interest does not overlap with scope of update. Approved by CM
Delia Sworm	Oncology Nurse Specialist	Nil	N/A	N/A	N/A	N/A	N/A
Steve Watkins	Oncologist	Direct, Financial	Member of advisory board for content of educational event regarding Cutaneous Squamous Cell Cancers and Cemipilimab immunotherapy for Sanofi GENZTME pharmaceutical.	May 2019	Novemb er 2019	11 th Novemb er 2019	Declare and participate Rationale: Interest specific to scope of update but occurred prior to appointment and has now ceased. No ongoing relationship with funder. Approved by SS
Steve Watkins	Oncologist	Direct, Financial	Member of advisory board looking at Cutaneous Squamous Cell Cancer treatment pathways and	Septem ber 2019	Novemb er 2019	2 nd Decemb er 2019	Declare and participate Rationale: Interest specific to scope of update but



			Cemipilimab immunotherapy within them for Sanofi GENZTME pharmaceutical.				occurred prior to appointment and has now ceased. No ongoing relationship with funder. Approved by SS
Sophie Wilne	Co-opted Paediatric Oncologist	Nil	N/A	N/A	N/A	N/A	N/A
Steven Connor	Consultant radiologist – Expert witness	Indirect, Financial	Private practice (<0.5% of work pertaining to melanoma)	2002	May 2021	Ongoing	Declare and participate Rational: Approved by SS

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.